Focal collaborates on restenosis treatments
This article was originally published in Clinica
Executive Summary
Ciba Pharmaceuticals and Chiron will receive exclusive rights in selected restenosis fields to Focal's drug delivery technology under a collaborative agreement. The two drug companies will individually develop and market the final products, while Focal will retain manufacturing rights. Joint funding for certain preclinical studies will be provided by Ciba and Chiron, which will each fund development of its own products thereafter. Focal will receive royalties on product sales.